CD19 and cancer: Functionally, NKTR-255 induces the proliferation and activation of NK and CD8+ T cells, increases the CD8+:regulatory T cell ratio, increases the accumulation and persistence of anti-CD19 CAR T cells in the bone marrow, and synergizes with monoclonal antibodies to enhance ADCC in cancer models.15